Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00481143
Status:
COMPLETED
Last Update Posted:
2017-05-31
First Post:
2007-05-31
Brief Title:
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Transfusion Dependent Iron Overload |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| Myelodysplastic Syndrome | View |
| MDS | View |
| iron overload | View |
| chelation | View |
| chelators | View |
| ICL670 | View |
| Deferasirox | View |
| serum ferritin | View |
| LIC | View |
| transfusional hemosiderosis | View |
| Refractory Anemia | View |
| RA | View |
| Refractory Anemia with Ringed Sideroblasts | View |
| RARS | View |
| blood transfusions | View |
| Mydelodysplastic Syndromes | View |